Cohort profile: the MCC-Spain follow-up on colorectal, breast and prostate cancers: study design and initial results.
Adult
Aged
Aged, 80 and over
Breast Neoplasms
/ genetics
Case-Control Studies
Colorectal Neoplasms
/ genetics
Environmental Exposure
Follow-Up Studies
Humans
Life Style
Male
Middle Aged
Multivariate Analysis
Neoplasm Staging
Prostatic Neoplasms
/ genetics
Quality of Life
Research Design
Risk Factors
Spain
/ epidemiology
Survival Analysis
MCC-Spain
breast cancer
cohort
colorectal cancer
epidemiology
prostate cancer
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
21 11 2019
21 11 2019
Historique:
entrez:
23
11
2019
pubmed:
23
11
2019
medline:
5
11
2020
Statut:
epublish
Résumé
Since 2016, the multicase-control study in Spain (MCC-Spain) has focused towards the identification of factors associated with cancer prognosis. Inception cohorts of patients with colorectal, breast and prostate cancers were assembled using the incident cases originally recruited. 2140 new cases of colorectal cancer, 1732 of breast cancer and 1112 of prostate cancer were initially recruited in 12 Spanish provinces; all cancers were incident and pathologically confirmed. Follow-up was obtained for 2097 (98%), 1685 (97%) and 1055 (94.9%) patients, respectively. Information gathered at recruitment included sociodemographic factors, medical history, lifestyle and environmental exposures. Biological samples were obtained, and 80% of patients were genotyped using a commercial exome array. The follow-up was performed by (1) reviewing medical records; (2) interviewing the patients by phone on quality of life; and (3) verifying vital status and cause of death in the Spanish National Death Index. Ninety-seven per cent of recruited patients were successfully followed up in 2017 or 2018; patient-years of follow-up were 30 914. Most colorectal cancers (52%) were at clinical stage II or lower at recruitment; 819 patients died in the follow-up and the 5-year survival was better for women (74.4%) than men (70.0%). 71% of breast cancers were diagnosed at stages I or II; 206 women with breast cancer died in the follow-up and the 5-year survival was 90.7%. 49% of prostate cancers were diagnosed at stage II and 32% at stage III; 119 patients with prostate cancer died in the follow-up and the 5-year survival was 93.7%. MCC-Spain has built three prospective cohorts on highly frequent cancers across Spain, allowing to investigate socioeconomic, clinical, lifestyle, environmental and genetic variables as putative prognosis factors determining survival of patients of the three cancers and the inter-relationship of these factors.
Identifiants
pubmed: 31753885
pii: bmjopen-2019-031904
doi: 10.1136/bmjopen-2019-031904
pmc: PMC6887054
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e031904Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
BMJ. 2015 Oct 06;351:h4901
pubmed: 26442924
Ann Oncol. 2018 Feb 1;29(2):377-385
pubmed: 29161337
Int J Cancer. 2017 Jul 1;141(1):83-93
pubmed: 28380695
Oncologist. 2010;15(3):308-16
pubmed: 20189976
Sci Rep. 2017 Feb 24;7:43263
pubmed: 28233817
BMJ Open. 2018 Jan 31;8(1):e019409
pubmed: 29391368
J Clin Oncol. 2014 Oct 1;32(28):3177-83
pubmed: 25092779
Urology. 1997 Dec;50(6):920-8
pubmed: 9426724
Clin Colorectal Cancer. 2019 Mar;18(1):e104-e116
pubmed: 30448100
BMC Cancer. 2016 Aug 19;16(1):658
pubmed: 27553083
Comput Methods Programs Biomed. 2018 Mar;155:199-208
pubmed: 29512500
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
PLoS One. 2016 Aug 10;11(8):e0159672
pubmed: 27508297
Clin Oncol (R Coll Radiol). 2019 Sep;31(9):630-636
pubmed: 31130340
Ann Surg. 2002 Jan;235(1):10-26
pubmed: 11753038
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
J Urol. 1992 Nov;148(5):1549-57; discussion 1564
pubmed: 1279218
Sci Rep. 2018 Feb 14;8(1):3036
pubmed: 29445177
Int J Cancer. 2015 Sep 1;137(5):1147-57
pubmed: 25530021
Int J Cancer. 2018 Jan 1;142(1):165-175
pubmed: 28884470
Int J Cancer. 2019 Nov 1;145(9):2597-2599
pubmed: 31232468
Am J Clin Oncol. 2019 Jul;42(7):588-595
pubmed: 31166208
Maturitas. 2017 Sep;103:8-15
pubmed: 28778338
Gac Sanit. 2006 Nov-Dec;20(6):421-3
pubmed: 17198617
Value Health. 2012 Jan;15(1):183-90
pubmed: 22264987
Gac Sanit. 2015 Jul-Aug;29(4):308-15
pubmed: 25613680